A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

Summary

RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving alemtuzumab together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving alemtuzumab together with rituximab and to see how well it works in treating patients with previously untreated B-cell chronic lymphocytic leukemia.

Timeline

Start

2005-09-26

Primary completion

2010-03-17

Completion

2013-01-24

Drugs

Indications